Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 4Phase 1 2Phase 1/2 1

Status

Completed 2Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1Endocrine 1

Conditions

Hypertension 2Diabetes Mellitus, Type 2 2Cushing Syndrome 2ACTH Syndrome, Ectopic 2Pituitary ACTH Hypersecretion 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Fallopian Tube Neoplasms 1

Interventions

Carboplatin 315Paclitaxel 303Cisplatin 250Docetaxel 238pembrolizumab 230Gemcitabine 214Pemetrexed 158Capecitabine 147Rituximab 144Bevacizumab 142Dexamethasone 125Fluorouracil 121Cyclophosphamide 102Trastuzumab 100Doxorubicin 96Nivolumab 93Prednisone 92Oxaliplatin 90atezolizumab 75Leucovorin 72durvalumab 69130-nm albumin-bound paclitaxel 68Injections 66Lenalidomide 63Irinotecan 62Bortezomib 56Letrozole 54Topotecan 53Fulvestrant 53Drug Therapy 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × INDUSTRY × relacorilant × Clear all
NCT04308590 2025-09-04

GRADIENT

Corcept Therapeutics

Phase 3 Completed
137 enrolled 25 charts

ACTH Syndrome, Ectopic, Cushing Syndrome, Diabetes Mellitus, Type 2, Hypertension

NCT03697109 2025-07-16

GRACE

Corcept Therapeutics

Phase 3 Completed
152 enrolled 28 charts
Endocrine

ACTH Syndrome, Ectopic, Cushing Syndrome, Diabetes Mellitus, Type 2, Hypertension, Pituitary ACTH Hypersecretion

NCT05257408 2025-04-16

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

Corcept Therapeutics

Phase 3 Active not recruiting
381 enrolled 1 FDA
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT04329949 2023-11-18

RELIANT

Corcept Therapeutics

Phase 3 Terminated
43 enrolled 17 charts
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡